Study To Assess Efficacy, Safety, Tolerability And Pharmacokinetics Of PF-07038124 Ointment In Participants With Atopic Dermatitis Or Plaque Psoriasis

Completed · Phase 2

Conditions studied: Atopic Dermatitis, Plaque Psoriasis

In brief

This study is being conducted to provide data on efficacy, safety, tolerability and PK of PF-07038124 ointment versus vehicle control in the treatment of mild to moderate AD and mild to moderate plaque psoriasis.

Key facts

Study ID

NCT04664153

Run by

Pfizer

People needed

104

Starts

2020-12-21

Expected to finish

2021-08-18

Last updated by the study team

2022-08-26

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Atopic Dermatitis (AD): Have been diagnosed with AD for at least 3 months; Have an Investigator's Global Assessment (IGA) score of 2 (mild), or 3 (moderate); Have AD covering 5% to 20% (inclusive) of BSA.
• Plaque psoriasis: Have been diagnosed with plaque psoriasis (psoriasis vulgaris) for at least 6 months; Have a Physician Global Assessment (PGA) score of 2 (mild), or 3 (moderate); Having plaque psoriasis covering 5% to 15% (inclusive) of BSA.

You may not qualify if…

• Presence of skin comorbidities that would interfere with study assessment or response to treatment.
• Current or recent history of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, metabolic, endocrine, pulmonary, cardiovascular, or neurological disease.
• Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.

Where it is running

• First OC Dermatology — Fountain Valley, California, United States
• Renaissance Research and Medical Group — Cape Coral, Florida, United States
• Olympian Clinical Research — Clearwater, Florida, United States
• Moonshine Research Center, Inc. — Doral, Florida, United States
• Clinical Neuroscience Solutions — Orlando, Florida, United States
• Center for Clinical Studies — Tampa, Florida, United States
• Dawes Fretzin Clinical Research Group, LLC — Indianapolis, Indiana, United States
• The Indiana Clinical Trials Center, PC — Plainfield, Indiana, United States
• Henry Ford Medical Center, New Center One — Detroit, Michigan, United States
• M3 Wake Research, Inc. — Raleigh, North Carolina, United States
• Oregon Dermatology and Research Center — Portland, Oregon, United States
• Clinical Neuroscience Solutions, Inc. dba CNS Healthcare — Memphis, Tennessee, United States
• studies in Dermatology, LLC — Cypress, Texas, United States
• Center for Clinical Studies — Houston, Texas, United States
• Center for Clinical Studies, LTD. LLP — Webster, Texas, United States
• Australian Clinical Research Network — Maroubra, New South Wales, Australia
• Emeritus Research — Camberwell, Victoria, Australia
• Dermatrials Research Inc. — Hamilton, Ontario, Canada
• Lynderm Research Inc. — Markham, Ontario, Canada
• DermEdge Research — Mississauga, Ontario, Canada
• Innovaderm Research Inc. — Montreal, Quebec, Canada
• Centre de Recherche Dermatologique du Quebec metropolitain — Québec, Canada
• NZOZ Specjalistyczny Osrodek Dermatologiczny DERMAL — Bialystok, Poland
• Mazowieckie Centrum Badań Klinicznych — Grodzisk Mazowiecki, Poland
• Centrum Medyczne Angelius Provita — Katowice, Poland

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.